Streamlining cell therapy manufacture: From clinical to commercial scale

BioProcess International

Volumn 10, Issue SUPPL. 3, 2012, Pages 24-49

  Davie, Natasha L ^a,b,e   Brindley, David A ^a,b,e   Culme Seymour, Emily J ^c,e   Mason, Chris ^d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c London Regenerative Medicine Network   (United Kingdom)

^d Advanced Centre for Biochemical Engineering   (United Kingdom)

^e Advanced Centre for Biochemical Engineering ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; MONOCLONAL ANTIBODY;

BIOPROCESS; CELL ASSAY; CELL CULTURE; CELL POPULATION; CELL THERAPY; CELLULAR PARAMETERS; COMMERCIAL PHENOMENA; CULTURE MEDIUM; GOLD STANDARD; HEALTH CARE COST; HUMAN; INFLAMMATION; LARGE SCALE PRODUCTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES CONCERNING CELLS; QUALITY CONTROL; REVIEW; SCALE UP;

EID: 84863548742     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (21)

1. Mason C, et al. Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential. Regen. Med. 6, 2011: 265-272.
2. Brindley DA, et al. The Impact of Market Volatility on the Cell Therapy Industry. Cell Stem Cell 9, 2011: 397-401.
3. Blendon RJ, Kim MK, Benson JM. The Public, Political Parties, and Stem-Cell Research. NEJM 365, 2011: 1853-1156.
4. Davie NL, et al. A Decade of Cell Therapy Clinical Trials 2000-2010. Regen. Med. in preparation.
5. Stenmark KR, et al. Hypoxia, Leukocytes, and the Pulmonary Circulation. J. Appl. Physiol. 98, 2005: 715-721. (Pubitemid 40129987)
6. OCTMA. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). US Food and Drug Administration: Rockville, MD, 2008.
7. CBER. Final Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. US Food and Drug Administration: Rockville, MD, 2011.
8. Mason C, Hoare M. Regenerative Medicine Bioprocessing: The Need to Learn from the Experience of Other Fields. Regen. Med. 1, 2006: 615-623.
9. Carman J, et al. Developing Assays to Address Identity, Potency, Purity, and Safety: Cell Characterization in Cell Therapy Process Development. Regen. Med. 2012: 85-100.
10. Brindley D, et al. Bioprocess Forces and Their Impact on Cell Behavior: Implications for Bone Regeneration Therapy. J. Tiss. Eng. 2011: 1-13.
11. Brindley DA, et al. Peak Serum: Implications for Cell Therapy Manufacturing. Regen. Med. 7, 2012: 7-13.
12. Kirouac DC, Zandstra PW. The Systematic Production of Cells for Cell Therapies. Cell Stem Cell 3, 2008: 369-381.
13. Rowley JA. Developing Cell Therapy Biomanufacturing Processes. Chem. Eng. Progr. November 2010: 50-55.
14. Aggarwal S. What's Fueling the Biotech Engine: 2010 to 2011. Nat. Biotechnol. 29, 2011: 1083-1089.
15. Rowley JA, Smith DW. Personal communication, 2011.
16. Rowley JA. Developing Scalable Bioproduction Processes: Integrating Upstream and Downstream Processing and Controlling Cost of Goods. Cell Therapy Bioprocessing 17-18th October 2011, Reston, VA. IBC Life Sciences: Westborough, MA.
17. Bonfiglio GA. Funding Options for Clinical-Stage Biotech Companies. 9th Annual Commercial Translation of Regenerative Medicine 14-16 November 2011, London, UK. Marcus Evans: London, UK.
18. Kemp P. Linking the Clinical Data to Manufacturing Experience. 9th Annual Commercial Translation of Regenerative Medicine 14-16 November 2011, London, UK. Marcus Evans: London, UK.
19. Sommerfield SS. Challenges in Biotechnology Production: Generic Processes and Process Optimization for Monoclonal Antibodies. Chem. Eng. Progr. 44, 2005: 1123-1137.
20. Mason C, Manzotti E. Regenerative Medicine Cell Therapies: Numbers of Units Manufactured and Patients Treated Between 1988 and 2010. Regen. Med. 5, 2010: 307-313.
21. Mason C, Manzotti E. The Translation Cycle: Round and Round in Cycles is the Only Way Forward for Regenerative Medicine. Regen. Med. 5, 2010: 153-135.